A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
Status:
Completed
Trial end date:
2017-09-05
Target enrollment:
Participant gender:
Summary
The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will
receive single-agent investigational study drug filanesib (ARRY-520). Patients will be
followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160
patients from North America and Europe will be enrolled in this study.
Eligible patients will have received at least two prior lines of therapy; have received prior
bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.